◌Obsidian Loop

About

An independent resource on ibogaine, OCD, evidence, and safety.

Obsidian Loop is an independent, evidence-first resource created to explain what research does — and does not — show about ibogaine for OCD. We prioritize careful descriptions of evidence limits, transparent safety concerns, and clear signals toward established care options.

Read the evidence review Safety & cardiac notes
Close-up detail photograph used as a visual accent for Obsidian Loop's About page

Our editorial approach

We collect, summarize, and contextualize peer-reviewed literature, clinical registries, regulatory advisories, and reputable clinical summaries to explain evidence quality, study limits, and safety signals. For claims about ibogaine we cross-check trial reports against registries and primary publications and link to source material in-line as we describe findings; when a procedural or experiential claim appears in public discussion we assess whether it is supported by controlled studies or case series.

As part of that process we reference authoritative bodies where relevant — for example, clinicians and researchers commonly consult established databases and guidance such as ClinicalTrials.gov for trial registration and summaries on trial design, and broad context about obsessive–compulsive disorder is available on Wikipedia at Obsessive–compulsive disorder to orient non‑specialist readers.

How we source information

Primary sources include peer‑reviewed journals, clinical trial registries, and official advisories from regulatory agencies. We prioritize direct citations to studies and their registration records, and where gaps exist we note them plainly. For claims about pharmacology or cardiac risk we also consult recognized educational resources such as the NIH's MedlinePlus and university clinic summaries; for example, general medication safety principles are frequently summarized on sites like MedlinePlus.

What we cover

Obsidian Loop explains the evidence landscape around ibogaine and related claims at a high level: study designs, participant characteristics, reported outcomes, and safety signals. Our organization pages and service descriptions outline topics and types of content rather than offering clinical pathways; for additional context about where people discuss experiential accounts or clinic listings, readers sometimes examine third‑party directories such as clinic listings in Tijuana or broader treatment-marketoverviews like treatment options in Mexico, which we reference strictly as examples of public reporting rather than endorsements.

We also note common public queries such as how long effects are reported to last and what street‑name variations exist in community discussion; illustrative public resources often include timelines or aggregated reports like questions about duration and contextual glossaries such as street-name references.

Because site visitors sometimes follow operational pathways, we include context about reported success rates and outcome claims with clear caveats; summaries that aggregate self‑reported outcomes are distinct from controlled trial evidence and are discussed with that distinction in mind — for example, aggregated success summaries are separate from clinical trial registries and commercial reporting such as aggregated success estimates. We also note locations and service descriptions found in public sources such as supervised ibogaine directories, but never present these as endorsements.

Editorial principles

  • Evidence before claims — we summarize study design, sample size, and outcome measures rather than amplifying anecdotes.
  • Safety transparency — when cardiac or other physiological risks appear in the literature we highlight them prominently.
  • Plain language — we translate technical material into clear statements for non‑specialist readers without oversimplifying limits.
  • Independence — we do not accept clinical referrals, patient placement fees, or commercial treatment sponsorships.

Our values reflect standards similar to scholarly communication and evidence synthesis methods taught at universities; readers interested in methodology can consult resources such as the Cochrane Collaboration's general guidance on systematic approaches at Cochrane or methodology primers on research synthesis hosted by major universities like Johns Hopkins Bloomberg School of Public Health for background.

Who this is for

This resource is intended for people affected by OCD, their supporters, and clinicians or researchers seeking clear context about ibogaine‑related claims and risks. If you are seeking clinical care, our services overview explains the kinds of informational support we describe; for actionable treatment decisions consult licensed clinicians and relevant specialty services.

Independent by design

Obsidian Loop is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its content is not medical or legal advice. We make this disclosure central to every page and repeat it in the footer so readers see it consistently across the site.